Hemodialysis Access Planning, Selection, and Creation

60.1Definition and principles of access planning

Hemodialysis access planning is governed by the End-Stage Kidney Disease (ESKD) Life-Plan, an individualized sequence matching access options to life expectancy, comorbidity, and dialysis trajectory KDOQI 2019. Planning spans the whole kidney-replacement trajectory, including peritoneal dialysis and pre-emptive transplantation and not only the immediate fistula, so vessel preservation protects future access sites. Timing anchors to anticipated dialysis need rather than a fixed eGFR trigger. Contemporary guidelines replace universal "fistula-first" mandates with patient-centered targets for arteriovenous fistulas (AVFs), arteriovenous grafts (AVGs), and central venous catheters (CVCs) UKKA 2025 · KDOQI 2019 Update.

Access provision is a multidisciplinary process rather than an isolated surgical procedure. Optimal vascular access requires coordinated nephrology, vascular surgery, anesthesia, and dialysis-nursing engagement to manage referral timing, device selection, vessel mapping, and access creation Association of Anaesthetists 2025 · AVF 2002.

60.2Preoperative assessment and vessel mapping

Preoperative assessment combines examination with imaging selected for the patient. The NKF implementation pathway calls for ultrasound mapping in patients with risk factors for access failure or vessel injury, or an examination that cannot adequately define the anatomy National Kidney. A meta-analysis of 18 studies supports routine mapping over selective use, demonstrating a reduction in primary AVF failure with an RCT-pooled risk ratio of 0.37 US Mapping Meta-analysis 2023. Registry data (Vascular Quality Initiative) report over 85% utilization of preoperative mapping for patients undergoing AVF or AVG placement VQI Mapping 2022.

Physical examination remains necessary to identify arterial insufficiency, visible superficial veins, prior incisions, and limb dominance. Measure internal vessel diameters, noting tourniquet conditions, vein depth, continuity, compressibility and distensibility, and arterial inflow and calcification ESVS 2018.

Vessel size and fistula creation

ESVS 2018 uses 2-mm artery/vein diameters for radiocephalic and 3-mm diameters for brachiocephalic or brachiobasilic AVFs as explanatory planning benchmarks, not graded exclusion cutoffs ESVS 2018. UKKA recommendation 3.3 advises counseling about poorer outcomes when either vessel is below 2 mm (1C), not automatic exclusion UKKA 2025.

Patient-level risk factors strongly predict the failure of an access to mature, independent of vessel mapping. The REDUCE FTM I prediction rule identifies four primary risk factors for failure to mature:

• Peripheral vascular disease (odds ratio 2.97).
• Coronary artery disease (odds ratio 2.83).
• Age >= 65 years (odds ratio 2.23).
• Non-white race (odds ratio 0.43 for white race) REDUCE FTM 2006.

60.3Access selection and sequencing

The access sequence prioritizes preserving future sites while delivering a functional circuit within the required clinical timeframe. Autogenous AVFs offer superior one-year primary (odds ratio 1.61), primary-assisted (odds ratio 1.69), and secondary patency compared with AVGs AVF vs AVG Meta-analysis 2025. Catheters carry elevated mortality hazards and are reserved as temporary bridges or last-resort long-term options for patients lacking viable surgical targets Romanian Registry 2025. In the nationwide registry, only 20% of patients began dialysis with a functioning AVF, catheter-based initiation carried more than twice the mortality hazard of a fistula, and median AVF survival was 39.1 months.

For vessel-size assessment, see Preoperative assessment and vessel mapping; for the artery-vein configuration and conduit, see Creation technique and maturation.

1. Assess Life-Plan, dialysis urgency, and vessel map.
2. Consider percutaneous AVF if strict anatomic criteria are met.
3. Select a distal radiocephalic AVF if vessels are suitable and maturation time permits.
4. Choose an upper-arm AVF (brachiobasilic or brachiocephalic) based on anatomy and failure risk.
5. Proceed to an AVG if autogenous maturation probability is low or catheter time must be minimized.
6. Place a CVC only as a bridge or when surgical options are exhausted.

60.4Creation technique and maturation

In the HFM observational cohort, unassisted maturation occurred in 53.1% after regional/local anesthesia and 40.3% after general anesthesia. The association persisted after patient and fistula adjustment but not after adjustment for clinical center (odds ratio 1.03, 95% CI 0.78-1.36). This study therefore does not establish an independent causal maturation advantage for anesthesia type Anaesthesia Type 2022.

Fistula and graft configurations

An autogenous AVF joins the patient's artery and vein; an AVG interposes a conduit. Radiocephalic access joins radial artery to cephalic vein at the wrist; brachiocephalic access joins brachial artery to cephalic vein near the elbow. Brachiobasilic access uses the deeper basilic vein, which generally needs superficialization or transposition for needling, either at creation or as a second operation UKKA 2025. Forearm loop grafts commonly connect brachial inflow to basilic outflow; an upper-arm straight graft may connect brachial artery to axillary vein. The word loop specifies geometry, not whether access is an AVF or an AVG; document inflow, outflow and conduit.

Maturation assessment

Postoperative ultrasound defines early maturation progress. In the Hemodialysis Fistula Maturation (HFM) cohort, AVF blood flow, vein diameter, and vein depth measured at 1 day, 2 weeks, and 6 weeks independently predict clinical maturation, providing stronger prognostic value than physical examination or case-mix factors alone HFM Maturation 2021 · HFM Ultrasound Predictors 2018. The 2019 KDOQI guideline defines functional maturation as a fistula that reliably delivers the prescribed dialysis with two needles in more than two-thirds of sessions across a 4-week period; assess clinical maturation by 4 to 6 weeks postoperatively and refer early when the access is not maturing. No minimum vessel diameter mandates fistula creation, though arteries or veins under roughly 2 mm warrant careful feasibility assessment KDOQI 2019.

Percutaneous endovascular AVF creation (e.g., using thermal-resistance anastomosis) delivers high technical success in suitably selected patients. In a pivotal trial, fused anastomoses were achieved in 95% of cases, and primary flow (>= 500 mL/min) and diameter (>= 4 mm) endpoints were met in 86% Ellipsys Pivotal Trial 2018. An individual-participant-data meta-analysis confirms 97% technical success and 82.1% maturation with mid-term patency comparable to surgical AVFs Percutaneous AVF IPD Meta-analysis 2022 · Ellipsys Technical Aspects 2023.

In a randomized trial of 649 patients with newly created grafts, extended-release dipyridamole 200 mg plus aspirin 25 mg twice daily increased 1-year primary unassisted patency to 28%, versus 23% with placebo: an absolute difference of 5 percentage points. The benefit concerned time to thrombosis or an intervention to maintain patency, not a demonstrated reduction in death or cumulative graft failure Dixon Dipyridamole RCT 2009.

Conduit material and lower-limb access

Synthetic ePTFE and biological bovine carotid artery are alternative AVG conduits, not native fistulas. A small randomized comparison (26 bovine-carotid versus 27 cuffed-ePTFE patients) reported higher one-year primary and assisted-primary patency with bovine carotid grafts, without a significant secondary-patency difference; this does not establish superiority across all access settings prospective 2011. ESVS recommendation 23 specifically considers a biological rather than synthetic graft when an AVF cannot be created and infection is present (IIa C) ESVS 2018.

Lower-limb options include femoral-vein transposition AVF and a thigh AVG. Assess leg arterial perfusion and iliocaval outflow; ESVS recommendation 22 considers femoral-vein transposition over a graft when lower-limb access is necessary (IIa B) ESVS 2018.

Cannulation timing separates graft types. Conventional grafts generally need a postoperative healing interval, commonly 2 to 4 weeks ESVS 2018. Early cannulation is device-specific: Gore describes ACUSEAL use within 24 hours, and lists heparin hypersensitivity, including previous type II heparin-induced thrombocytopenia, as a contraindication GORE. The 2025 ACUSEAL safety correction warns about delamination and avoiding oversized balloons during reintervention; it does not call for routine removal of already implanted grafts GORE 2025. Use the applicable current instructions for the implanted product rather than a shared 24-72-hour rule for all named grafts.

60.5Surveillance and complication prevention

Post-creation surveillance tracks progress toward cannulation, identifies failure to progress, and dictates the timing of catheter removal. Routine preemptive angioplasty of asymptomatic stenoses identified solely by ultrasound is not recommended in the absence of clinical indicators of access dysfunction KDOQI 2019 Update.

When clinically significant AVF stenosis requires treatment, cutting-balloon angioplasty demonstrates superior 6-month primary lesion patency over high-pressure balloon angioplasty (risk ratio 1.45), although overall clinical success rates remain similar Cutting Balloon Meta-analysis 2024.

Access pathways are subject to systemic disparities that influence surveillance. Elderly women initiating dialysis receive AVFs less often than men (adjusted odds ratio 0.57) and experience higher rates of unsuccessful or assisted AVF use (hazard ratio 1.46). This mandates rigorous monitoring of referral, mapping, and catheter-dependence rates in older female cohorts Gender Disparities 2019. Geographic variation is also pronounced; historical data reveal 21-fold higher AVF utilization in European facilities compared with US facilities after adjustment for patient characteristics DOPPS Europe vs US 2002.

60.6Areas of controversy

Optimal AVF cannulation needle direction is debated; non-randomized data suggest retrograde direction may lower KT/V and antegrade direction may lower recirculation, but randomized trials do not confirm these effects Cannulation Needle Direction 2023.

Maturation adjuncts such as photochemical balloon-catheter treatments and far-infrared therapy show experimental and pooled clinical promise for reducing intimal hyperplasia and improving unassisted patency, but remain investigational rather than standard care Far-Infrared Therapy Meta-analysis 2025 · Photochemical AVF Creation · 2023.

Biologic predictors, including mineral metabolism markers (FGF-23, PTH, calcium, phosphate) and bioinformatic inflammatory signatures, correlate with vein remodeling and maturation but are not yet validated as routine selection tools Mineral Metabolism 2019 · Bioinformatics AVF Predictors 2024.

Benchtop surveillance technologies, such as novel 3D ultrasound devices (EchoSure) operated by novices, achieve volume-flow accuracy comparable to expert duplex ultrasound, but their role in replacing formal vascular laboratory surveillance is not established 3D Ultrasound AVF Mapping 2023.

Further reading

• Pre-operative ultrasound mapping before arteriovenous fistula formation: an updated systematic review and meta-analysis. (2024). Preoperative ultrasound mapping for fistula creation. US Mapping Meta-analysis 2023
• Patency and maturation rates after forearm arteriovenous fistulas: systematic review with meta-analysis. (2025). Forearm fistula maturation and patency. Forearm AVF Meta-analysis 2025